## Core Concept
Hepatocellular carcinoma (HCC) is a type of liver cancer with various treatment modalities, including surgical resection, transplantation, locoregional therapies, and systemic therapies. Systemic therapies often involve targeted agents and immunotherapies.

## Why the Correct Answer is Right
Sorafenib, a multi-kinase inhibitor, is used in the treatment of advanced hepatocellular carcinoma. It works by inhibiting various intracellular (more than one type) and cell surface tyrosine kinases, some of which are thought to be involved in tumor growth, angiogenesis, and metastatic progression of cancer. This mechanism makes **Sorafenib** effective in treating HCC by reducing tumor growth and slowing disease progression.

## Why Each Wrong Option is Incorrect
- **Option A:** While certain chemotherapy agents may have some effect on various cancers, they are not specifically highlighted as first-line treatments for HCC compared to targeted therapies like Sorafenib.
- **Option B:** Similarly, other agents might be used in cancer treatment but are not specifically known for HCC treatment as Sorafenib is.
- **Option D:** This option might represent another treatment or agent not specifically known for its efficacy in HCC.

## Clinical Pearl / High-Yield Fact
A key point to remember is that Sorafenib was one of the first systemic therapies to demonstrate a survival benefit in patients with advanced HCC, making it a landmark treatment in oncology.

## Correct Answer Line
**Correct Answer: C. Sorafenib.**